Cathelijne H. van der Wouden

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Cathelijne H. van der Wouden, Anne Cambon‐Thomsen, Erika Cecchin et al. · Clinical Pharmacology & Therapeutics · 2016 · 288 citations · Full text

Relevant Pgx-markers, Genetic Epidemiology, Ubiquitous Pharmacogenomics +22

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines

Carin A.T.C. Lunenburg, Cathelijne H. van der Wouden, Marga Nijenhuis et al. · European Journal of Human Genetics · 2019 · 218 citations · Full text

Development of the <scp>PG</scp>x‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing

Cathelijne H. van der Wouden, Mandy H. van Rhenen, Wafa O. M. Jama et al. · Clinical Pharmacology & Therapeutics · 2019 · 96 citations · Full text

Consumer Perceptions of Interactions With Primary Care Providers After Direct-to-Consumer Personal Genomic Testing

Cathelijne H. van der Wouden, Deanna Alexis Carere, Anke H. Maitland‐van der Zee et al. · Annals of Internal Medicine · 2016 · 94 citations